Drug Pipeline

Naxitamab Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
4
Recruiting
4
Top Sponsors
Active Studies by Phase
Phase 2
4
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT05489887 Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma Neuroblastoma Recruiting
NCT06528496 N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in… High-risk Neuroblastoma Recruiting
NCT06540963 Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma Neuroblastoma Recruiting
NCT07537400 Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk… High-Risk Neuroblastoma Not Yet Recruiting
Phase 1/2
NCT07011654 Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative… Metastatic Triple-Negative Breast Cancer Recruiting
Sponsors Running Naxitamab Trials
Giselle Sholler (2) Memorial Sloan Kettering Cancer Center (1) M.D. Anderson Cancer Center (1) Shaare Zedek Medical Center (1)
Disease Areas
Breast Cancer (1) Triple-Negative Breast Cancer (1)
Get alerts when Naxitamab trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free